Important new standards for data collection in studies of advanced prostate cancer

Recently we noted that Morgans et al. had published information about a proposed, standardized set of patient-centered outcomes data for advanced prostate cancer that would facilitate cross-comparison of data from the many trials that take now place in the management of TxNxM+ prostate cancer. … READ MORE …

Chemo + ADT + RT: no benefit after 10 years

Earlier this month, we looked at the evidence of benefit for adding chemotherapy to androgen deprivation therapy (ADT) + radiation therapy (RT) for high-risk prostate cancer (see “Docetaxel with radiation in prostate cancer treatment”). … READ MORE …

Survival benefit of dose escalation for higher risk patients

As discussed in a previous article, there is a seeming discrepancy between the findings of Kalbasi et al. and RTOG 0126, at least for intermediate-risk patients. … READ MORE …

New trial of investigational immunotherapy in men on active surveillance

There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …

The cost of drugs for the treatment of cancer — in the pressure cooker

According to an announcement this morning from The Mayo Clinic, a group of 118 leading cancer experts has drafted proposals for reducing the high cost of cancer drugs and voiced support for a patient-based grassroots movement demanding action on the issue. … READ MORE …

Standardizing outcome measures in management of advanced prostate cancer

The Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement has finally been able to pull together a set of standardized patient-centered outcomes relevant to the evaluation of men in treatment for advanced forms of prostate cancer. … READ MORE …

Second-line treatment for men with radiorecurrent prostate cancer (the FORECAST trial)

An ongoing clinical trial available exclusively in the UK is the so-called FORECAST trial, designed to investigate focal forms of second-line therapy for men with progressive, radiorecurrent prostate cancer after first-line treatment with external beam radiation therapy. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,343 other followers